A Phase 1 Study of VELA-101 in Adult Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses via subcutaneous (SC) administration.
Epistemonikos ID: 099565b2b5a8f9345c63cdbbea9b292f444e69fc
First added on: Oct 08, 2026